## TROW: T. Rowe Price Group, Inc. - XLF: Financial Services

### Executive Summary

No thesis match: MRS_10 2.2% below STRENGTH zone (3.0-6.0%); PEG 4.78 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($102.51)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. 15,426 Shares in T. Rowe Price Group, Inc. $TROW Bought by Greenspring Advisors LLC**
- Source: MarketBeat | 20260105T135751 | Neutral | Relevance: 100%
- Greenspring Advisors LLC recently acquired a new stake of 15,426 shares in T. Rowe Price Group, Inc. (NASDAQ:TROW), valued at approximately $1.583 million, making it their 29th largest holding. T. Rowe Price reported strong Q3 earnings, exceeding analyst expectations with $2.81 EPS on 6% revenue growth, and offers a 4.9% annualized dividend yield. Despite institutional investors owning a significant portion of the company and recent share sales by insiders, analysts currently have a "Reduce" rating on the stock with an average price target of $108.31.

**2. T. Rowe Price Group, Inc. $TROW Stock Holdings Decreased by Mattern Capital Management LLC**
- Source: MarketBeat | 20260103T112728 | Neutral | Relevance: 100%
- Mattern Capital Management LLC significantly reduced its holdings in T. Rowe Price Group, selling 97.6% of its stake in Q3, leaving just 1,976 shares. This move contrasts with several other hedge funds that either increased their positions or initiated new ones in T. Rowe Price. Despite the reduction by Mattern Capital, T. Rowe Price Group reported strong Q3 earnings, beating analyst expectations, and maintains a substantial dividend yield of approximately 4.9%.

**3. Allen Wealth Management LLC Boosts Stock Position in T. Rowe Price Group, Inc. $TROW**
- Source: MarketBeat | 20260105T090921 | Neutral | Relevance: 97%
- Allen Wealth Management LLC significantly increased its stake in T. Rowe Price Group, Inc. (NASDAQ: TROW) by 459.3% in Q3, now owning 13,855 shares valued at $1.422 million, making it their 25th largest holding. Despite this institutional accumulation, analyst sentiment for T. Rowe Price is largely "Reduce" with a consensus price target of $108.31, reflecting more Hold and Sell recommendations. The company recently surpassed quarterly EPS estimates and announced a quarterly dividend of $1.27 per share, yielding approximately 4.9%.

**4. Technical Reactions to TGRW Trends in Macro Strategies**
- Source: Stock Traders Daily | 20260103T130935 | Somewhat-Bullish | Relevance: 64%
- This article analyzes T. Rowe Price Growth Stock Etf (NASDAQ: TGRW), highlighting weak near-term sentiment despite potential long-term strength. It details an exceptional risk-reward short setup and provides institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.

**5. Who Owns Cencora? Top Shareholders and Recent Insider Activity**
- Source: TIKR.com | 20260105T160756 | Neutral | Relevance: 63%
- Cencora, Inc. (NYSE: COR) is a global pharmaceutical services company with a market value of approximately $65.7 billion. Its shareholder base is dominated by large institutional investors like The Vanguard Group and BlackRock, providing ownership stability. While hedge funds such as Balyasny Asset Management and Millennium Management have increased their positions, recent insider trades appear modest and related to personal portfolio management rather than signaling a shift in future business performance.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Keefe, Bruyette | $115 | $117 | -2% |
| 2025-12-17 | Morgan Stanley | $128 | $126 | +2% |
| 2025-12-12 | Barclays | $102 | $101 | +1% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Keefe, Bruyette | main | Market Perform |
| 2025-12-17 | Morgan Stanley | main | Equal-Weight |
| 2025-12-12 | Barclays | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 29 ($0.38M) |
| Sells | 15 ($7.33M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.1% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 8 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (-0.1%)
- Blackrock Inc.: 9.4% (-1.6%)
- State Street Corpora: 6.5% (-2.7%)
- Charles Schwab Inves: 3.6% (+1.1%)
- Geode Capital Manage: 2.8% (+1.0%)

### Key Risks

1. Insider selling cluster: $7.3M in recent transactions.
2. Valuation stretched: PEG 4.8x requires aggressive growth execution.
3. Elevated short interest (11.8%): bears positioning against stock.

### Catalysts

- Momentum building: MRS_10 improving +2.6% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 4.78 signals overvaluation risk, limited margin of safety. Quality metrics strong (ROA 10%, margin 29%). Balance sheet: strong liquidity (11.4x), low leverage (D/E 0.26). Insider selling cluster ($7.3M in 90 days), potential headwind. Institutional flow bearish (8 selling vs 2 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $23.4B |
| Beta | 1.53 |
| 52W Range | $77.85 - $118.32 |
| Short Interest | 11.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.78 |
| Forward P/E | 10.4 |
| Current P/E | 11.0 |
| YoY Growth | 5.9% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -0.4% to 2.2% (+2.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.8pp (needs >3.0% for momentum thesis). MRS_5 at 1.9% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +MUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.21% (CS: 70) | Neutral |
| RSI_14 | 60.1 | Neutral |
| MACD Histogram | 0.06 | Bullish |
| vs SMA20 | 1.020x | Above |
| vs SMA50 | 1.034x | Above |
| vs SMA200 | 1.066x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $106.49
- **Stop Loss:** $102.51 (3.7% risk)
- **Target:** $110.47 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 346
- **Position Value:** $36,845.54
- **Portfolio %:** 36.85%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-06 (Est: $2.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.54 | $2.81 | +10.5% |
| 2025Q2 | $2.13 | $2.24 | +4.9% |
| 2025Q1 | $2.13 | $2.23 | +4.7% |
| 2024Q4 | $2.21 | $2.12 | -4.1% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_10*